Identification of BRAF p. V600E-Mutant and Wild-Type by MR Imaging in Pleomorphic Xanthoastrocytoma and Anaplastic Pleomorphic Xanthoastrocytoma

BACKGROUND AND PURPOSE

Compared with BRAF p. V600E wild-type pleomorphic xanthoastrocytoma, BRAF p. V600E-mutant pleomorphic xanthoastrocytoma showed a higher survival rate. In this study, we focused on finding preoperative MR imaging differences between BRAF p. V600E mutant and wild-type in pleomorphic xanthoastrocytoma and anaplastic pleomorphic xanthoastrocytoma.

MATERIALS AND METHODS

Twenty-three patients with pathologically confirmed pleomorphic xanthoastrocytoma or anaplastic pleomorphic xanthoastrocytoma in our hospital were retrospectively analyzed from January 2015 to December 2020. They were divided into a BRAF p. V600E-mutant group (including 6 pleomorphic xanthoastrocytomas and 5 anaplastic pleomorphic xanthoastrocytomas) and a wild-type group (including 8 pleomorphic xanthoastrocytomas and 4 anaplastic pleomorphic xanthoastrocytomas). The preoperative MR imaging characteristics of these groups were statistically compared.

RESULTS

The wild-type pleomorphic xanthoastrocytoma group presented with more aggressive conventional and advanced MR imaging features than the mutant pleomorphic xanthoastrocytoma group, including greater mean maximum tumor diameter (3.1 [SD, 0.9] cm versus 1.7 [SD, 0.4 ] cm, P < .05), more frequent heterogeneous contrast enhancement of solid portions (100% versus 0%, P < .001), more obvious peritumoral edema (mean, [2.1 SD, 0.7] cm versus 0.6 [SD, 0.2] cm, P < .01), and lower mean minimum relative ADC (896 [SD, 86] versus 988 [SD, 73], P < .05) and mean relative ADC (1060 [SD, 159] versus 1248 [SD, 116], P < .05) on DWI. However, there was no significant difference in either conventional or advanced MR imaging features between the wild-type anaplastic pleomorphic xanthoastrocytoma group and the mutant anaplastic pleomorphic xanthoastrocytoma group.

CONCLUSIONS

Neurosurgeons should carefully interpret MR images before an operation and select appropriate surgical strategies according to genotype prediction.

External validation of the PRECISE-DAPT score in an Asian cohort of patients with acute coronary syndrome post-percutaneous coronary intervention

Background

Dual antiplatelet therapy (DAPT) is a key treatment in acute coronary syndrome (ACS) patients after percutaneous coronary intervention (PCI), and the PRECISE-DAPT score is one of the risk assessment tools developed to guide its optimal duration. However, the PRECISE-DAPT derivation cohorts were largely based on Western populations and it remains unclear whether the score is able to demonstrate good predictive value in Asian populations.

Objective

To validate the performance of the PRECISE-DAPT score in a nationwide Asian cohort of ACS patients who underwent PCI and with subsequent DAPT.

Methods

Patients admitted with ACS between January 2012 and December 2014 were extracted from the Singapore Cardiac Longitudinal Outcomes Database (SingCLOUD). The primary outcome was major adverse cardiovascular events (MACE), a composite of deaths, ischemic and hemorrhagic strokes, and recurrent myocardial infarction. The PRECISE-DAPT score was calculated for each patient and was used to stratify patients into low bleeding risk (LBR) (score &lt;25) and high bleeding risk (HBR) (score ≥25) groups (Figure 1). The PRECISE-DAPT guidelines propose that patients with LBR follow a DAPT regimen of 12 months, while patients with HBR follow a DAPT regimen of 3 months followed by aspirin or clopidogrel monotherapy for the rest of the year. Medication adherence to the PRECISE-DAPT guidelines with a proportion of days covered (PDC) of 80% over the 1-year period post-PCI was taken as the cutoff to define adherence, i.e. patients with at least 80% of days covered were defined as adherent. Multivariate Cox regression analysis adjusted for age, gender, ethnicity, smoking status, prior MI, prior PCI and diabetes mellitus was applied to examine the association between the PRECISE-DAPT adherence and MACE. Score discrimination using c-statistic were calculated and calibration curves were visually assessed.

Results

A total of 1135 patients were analyzed. The PRECISE-DAPT score of the adherent group (n=486) was lower compared to the non-adherent group, that made up the majority (n=649) [16.8 (± 9.63) vs 30.37 (± 18.4), p&lt;0.001]. The overall incidence rate of MACE in this cohort was 14.3% and bleeding rate was 1.5%. Non-adherence to PRECISE-DAPT guidelines was independently associated with MACE at 1 year [OR 1.48, 95% CI 1.03 – 2.13, p=0.033] (Figure 1). Receiver-operating characteristic (ROC) analysis demonstrated that the PRECISE-DAPT score in predicting MACE has an area under curve (AUC) of 0.644 [95% CI 0.603, 0.685] (Figure 2) with a sensitivity of 42.8% and specificity of 80.2%.

Conclusion

The PRECISE-DAPT score is able to predict MACE in Asian patients with ACS treated with PCI with high specificity but is not sensitive. The lower AUC value derived suggests that other important factors potentially contribute to the development of MACE in this cohort. Further research is warranted to identify factors that may improve its discriminative performance.

Funding Acknowledgement

Type of funding sources: Public grant(s) – National budget only. Main funding source(s): National Medical Research Council (NMRC) Figure 1. Cox regression for MACEFigure 2. Histogram and AUC Curve

Clinical features and survival in pulmonary Takayasu's arteritis associated pulmonary hypertension: a national registry study

Background

The clinical features and long-term outcomes of patients with pulmonary Takayasu's arteritis associated pulmonary hypertension (PTA-PH) have not been well studied.

Purpose

To assess the clinical characteristics and long-term survival outcome in patients with PTA-PH.

Methods

We conducted a multi-center cohort study using the clinical, functional, and hemodynamic data from the National Rare Diseases Registry System of China. Patients with Takayasu's arteritis and pulmonary artery involvement, who fulfilled the 1990 American College of Rheumatology and/or modified Ishikawa criteria, from 13 referral centers of China, were included. The diagnosis of pulmonary hypertension (PH) was confirmed by right heart catheterization findings. The primary outcome was time from diagnosis of PTA-PH to the occurrence of all-cause death.

Results

Between Jan. 2007 and Jan. 2019, a total of 140 patients with PTA-PH were included, with a mean age of 41.4±14.3 years at diagnosis, and a female predominance (81%). The most common symptoms were exertional dyspnea (91%) and hemoptysis (36%). The majority of patients (87%) exhibited bilateral pulmonary artery involvement. Pulmonary lobar artery was the most frequently affected vessel (100%), followed by segmental artery (82%) and left/right pulmonary artery trunk (49%). Severely compromised hemodynamic profiles were identified in these patients, indicating by elevated mean pulmonary artery pressure (48, interquartile range [IQR] 38–59 mm Hg) and pulmonary vascular resistance (9.4, IQR 5.7–13.3 Wood U). The overall 1-year, 3-year, and 5-year survival rates in PTA-PH were 94.0%, 83.2%, and 77.2%, respectively (Figure). Predictors associated with increased risk of all-cause death were the presence of syncope (hazard ratio [HR]: 4.88; 95% CI: 1.62–14.74; p=0.005), N-terminal pro-B type natriuretic peptide level (HR: 1.04; 95% CI: 1.02–1.06; p&lt;0.001), and right atrial pressure (HR: 1.07; 95% CI: 1.02–1.73; p=0.009).

Conclusions

In this national registry study, the reported clinical features and long-term prognosis of patients with PTA-PH are novel findings. These findings may provide new insights on this specific pulmonary hypertension entity.

Funding Acknowledgement

Type of funding sources: Public grant(s) – National budget only. Main funding source(s): The National Key Research and Development Program of China Kaplan-Meier plot for survival rate

Clinical characteristics and outcomes of myocardial infarction with nonobstructive coronary arteries

Background

Myocardial infarction with nonobstructive coronary arteries (MINOCA) is caused by a heterogenous group of conditions with clinically significant sequelae.

Purpose

This study aims to compare the clinical characteristics and prognosis of MINOCA with myocardial infarction with obstructive coronary artery disease (MICAD).

Methods

Data was obtained from the Singapore Cardiac Longitudinal Outcomes Database (SingCLOUD), a national multicenter registry of patients with cardiovascular disease. Patients with a first presentation of acute myocardial infarction who underwent coronary angiography between 1 January 2011 and 31 December 2014 were extracted from the database. Follow up was conducted until 31 December 2017. Subjects were classified as having either MICAD or MINOCA based on angiographic findings. The primary outcomes were all-cause mortality and major adverse cardiac events (MACE) defined as a composite of all-cause mortality, recurrent myocardial infarction, hospitalization for heart failure and ischemic stroke.

Results

All 4124 patients who met the inclusion criteria were included in this study, of which 159 (3.9%) were diagnosed with MINOCA. Patients with MINOCA were more likely to be female, present with a non-ST elevation myocardial infarction (NSTEMI), have a higher left ventricular ejection fraction and less likely to have diabetes mellitus, previous ischemic stroke or smoking history. Over a mean follow-up duration of 4.5 years, MINOCA patients had a lower incidence of all-cause mortality (10.1% vs. 16.5%, p=0.030) and MACE (20.8% vs. 35.5%, p&lt;0.0001) compared to patients with MICAD. On multivariable analysis, patients with MINOCA had a significantly lower risk of all-cause mortality (HR 0.42; 95% CI 0.21–0.82; p=0.011), MACE (HR 0.42; 95% CI 0.26–0.69; p=0.001) and recurrent myocardial infarction (HR 0.35; 95% CI 0.15–0.85; p=0.021). Within the MINOCA group, older age, higher creatinine, a STEMI presentation and the absence of antiplatelet use predicted all-cause mortality and MACE.

Conclusions

While patients with MINOCA had better clinical outcomes compared to MICAD patients, MINOCA is not a benign entity with about one in five patients experiencing a major adverse cardiovascular event in the mid-term.

Funding Acknowledgement

Type of funding sources: Public grant(s) – National budget only. Main funding source(s): National Medical Research Council Project Grant

Adverse events in acute myocardial infarction patients: the DAPT Score for risk stratification in an Asian population

Background

Dual antiplatelet therapy (DAPT) is essential in mitigating adverse ischemic events after myocardial infarction (MI), and current guidelines have recommended the therapy to be administered for at least 1 year. Though prolonged DAPT helps to reduce ischemic events in high-risk patients, it can also increase the risk of significant bleeding. Risk stratification tools, such as the DAPT Score, can help to identify patients who are most or least likely to benefit from prolonged DAPT.

Purpose

To evaluate the performance of the DAPT Score as a predictor of major adverse cardiovascular events (MACE) in an Asian cohort who underwent percutaneous coronary intervention (PCI) for MI.

Methods

The analysis cohort consisted of 2086 MI patients (86% of primary PCI patients) who were admitted to Singaporean hospitals between 2012 and 2014. Demographic, clinical and therapeutic data regarding the index hospitalisation and 12-month follow-up period were collected. Patients were grouped according to their DAPT Score (high ischemic vs high bleeding risk) and DAPT duration (12 vs &lt;12 months; Figure 1). The primary endpoint was MACE (all-cause mortality, recurrent MI and stroke). MACE as an outcome was evaluated using multivariable Cox regression adjusted for age, gender, ethnicity, smoking status, prior MI, PCI or coronary artery bypass graft, hypertension, dyslipidaemia, cerebrovascular disease, diabetes mellitus, family history of coronary artery disease, vein graft stent and type of MI at presentation.

Results

The overall incidence rate of MACE in this cohort was 12.3%. There was a significantly higher MACE rate in Group 2 patients compared to Group 1 patients (high ischemic risk and &lt;12-month DAPT vs high ischemic risk and 12-month DAPT; hazard ratio: 1.37, 95% confidence interval: 1.02–1.83, P=0.038). No other significant differences in MACE rates were observed among the rest of the groups (Group 3: 1.44 [0.89–2.34]; Group 4: 1.15 [0.61–2.16], P&gt;0.050). Furthermore, MACE was independently associated with diabetes, hypertension, prior MI and cerebrovascular disease (1.49 [1.10–2.02], 1.43 [1.00–2.05], 1.41 [1.01–1.98], 3.06 [2.15–4.37], respectively, P&lt;0.050). Patients &lt;65 years and males were found to be protected against MACE (0.71 [0.51–0.99], 0.72 [0.52–0.99], respectively, P&lt;0.050). The overall bleeding rate was 2.2% (Group 1: 2.0%; Group 2: 1.7%; Group 3: 6.0%; Group 4: 0.7%).

Conclusions

The DAPT Score predicted MACE up to 12 months after PCI in MI patients with high ischemic risk and &lt;12 months of DAPT. This highlights the importance of adequate duration of DAPT in high ischemic risk MI patients. Moreover, the elderly, female, diabetic, hypertensive and those with prior cerebrovascular disease or MI were at increased risk for MACE.

Funding Acknowledgement

Type of funding sources: Public grant(s) – National budget only. Main funding source(s): National Medical Research Council - Health Services Research Grants (Ministry of Health, Singapore) CohortsCox regression for MACE

Branching Fraction Measurements of the Rare B_{s}^{0}→ϕμ^{+}μ^{-} and B_{s}^{0}→f_{2}^{'}(1525)μ^{+}μ^{-} Decays

The branching fraction of the rare B_{s}^{0}→ϕμ^{+}μ^{-} decay is measured using data collected by the LHCb experiment at center-of-mass energies of 7, 8, and 13 TeV, corresponding to integrated luminosities of 1, 2, and 6  fb^{-1}, respectively. The branching fraction is reported in intervals of q^{2}, the square of the dimuon invariant mass. In the q^{2} region between 1.1 and 6.0  GeV^{2}/c^{4}, the measurement is found to lie 3.6 standard deviations below a standard model prediction based on a combination of light cone sum rule and lattice QCD calculations. In addition, the first observation of the rare B_{s}^{0}→f_{2}^{'}(1525)μ^{+}μ^{-} decay is reported with a statistical significance of 9 standard deviations and its branching fraction is determined.

Performance analysis and implementation of a scanning tunneling potentiometry setup: Toward low-noise and high-sensitivity measurements of the electrochemical potential

Scanning tunneling potentiometry allows for studying charge transport on the nanoscale to relate the local electrochemical potential to morphological features of thin films or two-dimensional materials. To resolve the influence of atomic-scale defects on the charge transport, sub-µV sensitivity for the electrochemical potential is required. Here, we present a complete analysis of the noise in scanning tunneling potentiometry for different modes of operation. We discuss the role of various noise sources in the measurements and technical issues for both dc and ac detection schemes. The influence of the feedback controller in the determination of the local electrochemical potential is taken into account. Furthermore, we present a software-based implementation of the potentiometry technique in both dc and ac modes in a commercial scanning tunneling microscopy setup with only the addition of a voltage-controlled current source. We directly compare the ac and dc modes on a model resistor circuit and on epitaxial graphene and draw conclusions on the advantages and disadvantages of each mode. The effects of sample heating and the occurrence of thermal voltages are discussed.

Observation of the Mass Difference between Neutral Charm-Meson Eigenstates

A measurement of mixing and CP violation in neutral charm mesons is performed using data reconstructed in proton-proton collisions collected by the LHCb experiment from 2016 to 2018, corresponding to an integrated luminosity of 5.4  fb^{-1}. A total of 30.6 million D^{0}→K_{S}^{0}π^{+}π^{-} decays are analyzed using a method optimized for the measurement of the mass difference between neutral charm-meson eigenstates. Allowing for CP violation in mixing and in the interference between mixing and decay, the mass and decay-width differences are measured to be x_{CP}=[3.97±0.46(stat)±0.29(syst)]×10^{-3} and y_{CP}=[4.59±1.20(stat)±0.85(syst)]×10^{-3}, respectively. The CP-violating parameters are measured as Δx=[-0.27±0.18(stat)±0.01(syst)]×10^{-3} and Δy=[0.20±0.36(stat)±0.13(syst)]×10^{-3}. This is the first observation of a nonzero mass difference in the D^{0} meson system, with a significance exceeding seven standard deviations. The data are consistent with CP symmetry and improve existing constraints on the associated parameters.

[Quantitative analysis of differential proteins in liver tissues of patients with non-alcoholic steatohepatitis using iTRAQ technology]

OBJECTIVE

To screen differentially expressed proteins (DSPs) in the liver tissues of patients with nonalcoholic steatohepatitis (NASH) using proteomic technologies to identify potential therapeutic targets of NASH.

METHODS

Liver tissue specimens were obtained from 3 patients with pathologically confirmed NASH and 3 normal control subjects. The total proteins were extracted from the specimens, and iTRAQ reagent was used to label the peptides for liquid chromatography tandem mass spectrometry (LC-MS/MS) detection. The DSPs were identified by comparing the data against UniProt protein database using Mascot2.3.02 software and were annotated and enriched using GO database; KEGG database was used for enrichment of the pathways involving these proteins. Real-time fluorescent quantitative PCR (qPCR) was performed to detect the mRNA expressions of the significant DSPs in NASH.

RESULTS

By the criteria that a DSP has >1.2 or < 0.8 fold difference between NASH group and the control group and with P < 0.05 as the threshold, a total of 648 significant DSPs in NASH were identified, including 246 up-regulated and 402 down-regulated proteins. GO functional enrichment analysis showed that the DSPs were involved mainly in small molecule metabolism, organic acid metabolism, oxygen acid metabolism and other biological processes, and were enriched in KEGG pathways including the metabolic pathways, complement coagulation cascades, and ribosomes. Among the 25 DEPs with a fold difference >2.0 or < 0.5 (P < 0.05), 6 proteins showed consistent results between qPCR verification and proteomic analysis, including 5 down-regulated proteins: Jumonji protein (JARID2), Lebasillinlike protein (LCA5L), synaptophysin 1 (SYN1) and collagen α-1 (XIII) chain (COL13A1), FYVE, RhoGEF and PH domain protein 5 (FGD5), and 1 upregulated protein glutathione S-transferase Mu 4 (GSTM4).

CONCLUSION

We identified 648 DEPs inthe liver tissue of patients NASH using iTRAQ technology and bioinformatics methods, and among them JARID2, SYN1, COL13A1, FGD5, and GSTM4 may serve as the key target proteins of NASH.

Observation of New Resonances Decaying to J/ψK^{+} and J/ψϕ

The first observation of exotic states with a new quark content cc[over ¯]us[over ¯] decaying to the J/ψK^{+} final state is reported with high significance from an amplitude analysis of the B^{+}→J/ψϕK^{+} decay. The analysis is carried out using proton-proton collision data corresponding to a total integrated luminosity of 9  fb^{-1} collected by the LHCb experiment at center-of-mass energies of 7, 8, and 13 TeV. The most significant state, Z_{cs}(4000)^{+}, has a mass of 4003±6_{-14}^{+4}  MeV, a width of 131±15±26  MeV, and spin parity J^{P}=1^{+}, where the quoted uncertainties are statistical and systematic, respectively. A new 1^{+}  X(4685) state decaying to the J/ψϕ final state is also observed with high significance. In addition, the four previously reported J/ψϕ states are confirmed and two more exotic states, Z_{cs}(4220)^{+} and X(4630), are observed with significance exceeding 5 standard deviations.

[Effect of metformin and rosiglitazone in non-obese polycystic ovary syndrome women with insulin resistance]

Objective: To investigate effects of metformin and rosiglitazone in non-obese polycystic ovary syndrome (PCOS) women with insulin resistance. Methods: Totally 200 non-obese PCOS women with insulin resistance in West China Second Hospital of Sichuan University were enrolled into this study from Sep. 2013 to Jun. 2016, and were randomly divided into two treatment groups: metformin group (1 500 mg/d) and rosiglitazone group (4 mg/d). The treatment lasted for 6 months. Their clinical and biochemical parameters were collected and compared. Results: In both groups, menstrual cycles [metformin group (37±4) days, rosiglitazone group (35±4) days] were shorter after treatment for 6 months (both P<0.01). After treatment for 6 months, body mass index [metformin group (21.6±1.6) kg/m², rosiglitazone group (21.7±1.7) kg/m²] decreased in both groups (both P<0.01); decreased LH/FSH ratio (metformin group 1.67±0.80, rosiglitazone group 1.70±0.83) was also observed (both P<0.05). After treatment for 6 months, fasting insulin level [metformin group (13.5±5.1) mU/L, rosiglitazone group (12.7±5.6) mU/L] and homeostasis model assessment-insulin resistance index (metformin group 3.0±1.2, rosiglitazone group 2.8±1.2) were decreased in both groups (all P<0.01). Conclusions: For non-obese PCOS insulin resistance patients, screening of anthropometric and metabolic parameters is necessary. For PCOS with insulin resistance, lifestyle plus insulin sensitizers such as metformin could improve their clinical symptoms, correct the biochemical and metabolic dysfunction.

[MicroRNA-424 inhibits autophagy and proliferation of hepatocellular carcinoma cells by targeting ATG14]

OBJECTIVE

To determine whether miR-424 affects cancer cell proliferation and autophagy through ATG14 in hepatocellular carcinoma (HCC) cells.

METHODS

We detected miR-424-5p and ATG14 expression levels in surgical specimens of HCC and adjacent tissues and in different HCC cell lines (HepG2, SMMC-7721, Huh-7, MHCC97H, and HCCLM3) and normal human hepatocyte LO2 cells using qRT-PCR and Western blotting. In the cell transfection experiments, we observed the effects of miR-424-5p knockdown in Huh-7 cells and the effects of overexpression miR-424-5p and ATG14 in HCCLM3 cells on the proliferation, cell cycle, apoptosis and expression levels of autophagy-related proteins (LC3, Beclin1 and p62). Dual luciferase reporter assay was used to verify the possible interaction between miR-424-5p and ATG14.

RESULTS

In HCC tissues and cells, ATG14 was highly expressed and miR-424-5p expression was downregulated. In HCC cells, overexpression of miR-424-5p obviously suppressed cell proliferation and promoted cell apoptosis (P < 0.05), while inhibiting miR-424-5p or overexpressing ATG14 significantly promoted cell proliferation and inhibited cell apoptosis (P < 0.05). Dual luciferase reporter assay indicated that miR-424-5p inhibits HCC cells by targeting ATG14. In addition, inhibition of miR-424-5p and overexpression of ATG14 both enhanced the expressions of LC3-ΙΙ/LC3-Ι and Beclin1 and decreased p62 expression (P < 0.05), but miR-424-5p overexpression reduced the expressions of LC3-ΙΙ/LC3-Ι and Beclin1 and increased p62 expression (P < 0.05).

CONCLUSION

MiR-424 inhibits HCC cell autophagy and proliferation through regulating ATG14.

Coherent spin qubit transport in silicon

A fault-tolerant quantum processor may be configured using stationary qubits interacting only with their nearest neighbours, but at the cost of significant overheads in physical qubits per logical qubit. Such overheads could be reduced by coherently transporting qubits across the chip, allowing connectivity beyond immediate neighbours. Here we demonstrate high-fidelity coherent transport of an electron spin qubit between quantum dots in isotopically-enriched silicon. We observe qubit precession in the inter-site tunnelling regime and assess the impact of qubit transport using Ramsey interferometry and quantum state tomography techniques. We report a polarization transfer fidelity of 99.97% and an average coherent transfer fidelity of 99.4%. Our results provide key elements for high-fidelity, on-chip quantum information distribution, as long envisaged, reinforcing the scaling prospects of silicon-based spin qubits.

Cut-offs for defining uterine prolapse using transperineal ultrasound in Chinese women: prospective multicenter study

OBJECTIVE

Transperineal ultrasound is a simple and highly repeatable method that has been used increasingly in the quantification of pelvic organ prolapse, but abnormal uterine descent on ultrasound in Chinese women is still poorly defined. We aimed to determine the optimal cut-off to define abnormal uterine descent on transperineal ultrasound in Chinese women.

METHODS

This prospective multicenter study recruited women who were examined in tertiary-level gynecological centers, due to symptoms of lower urinary tract and/or pelvic floor dysfunction, between February 2017 and September 2018. All recruited women underwent a standardized interview, pelvic organ prolapse quantification (POP-Q) examination, and four-dimensional transperineal ultrasound examination. On ultrasound, uterine descent was measured relative to the posteroinferior margin of the symphysis pubis during maximum Valsalva maneuver. The optimal cut-off value for definition of abnormal uterine descent was selected as the value with the highest Youden index and the diagnostic performance of this cut-off for the prediction of prolapse symptoms and POP-Q stage was assessed and compared by means of the area under the receiver-operating-characteristics curve (AUC).

RESULTS

In total, 538 Chinese women, with a mean age of 39.4 (range, 18-81) years, were enrolled into the study. Both uterine descent on transperineal ultrasound (P < 0.001) and POP-Q stage (P < 0.001) were associated strongly with presence of prolapse symptoms. Uterine descent on ultrasound was associated significantly with POP-Q stage for apical compartment prolapse (P < 0.001). The optimal cut-off value for the definition of abnormal uterine descent on transperineal ultrasound during maximum Valsalva maneuver in the prediction of prolapse symptoms was 4.79 mm above the symphysis pubis (AUC, 0.75 (95% CI, 0.71-0.78)), while the optimal cut-off values in the prediction of prolapse of POP-Q Stage ≥ 1 and POP-Q Stage ≥ 2 were 6.63 mm above the symphysis pubis (AUC, 0.83 (95% CI, 0.80-0.86)) and 8.42 mm below the symphysis pubis (AUC, 0.85 (95% CI, 0.82-0.88)), respectively.

CONCLUSIONS

The optimal cut-off value to define abnormal uterine descent on transperineal ultrasound during maximum Valsalva maneuver for the prediction of prolapse symptoms in this population of Chinese women was 4.79 mm above the symphysis pubis, close to that for predicting apical compartment prolapse of POP-Q Stage ≥ 1 (6.63 mm above the symphysis pubis). These are somewhat different from values described previously in mainly Caucasian populations. Ethnic differences should be taken into account in the evaluation of pelvic organ prolapse using transperineal ultrasound. © 2020 International Society of Ultrasound in Obstetrics and Gynecology.

[Development and functional validation of a nano-delivery system of miR-16/polypeptide targeting ovarian cancer cells]

OBJECTIVE

To develop a nano-delivery system for targeted delivery of miR-16/polypeptide for enhancing cisplatin sensitivity of ovarian cancer.

OBJECTIVE

R9-SS-R9 and cRGD-R9-SS-R9 peptides were synthesized and self-assembled with miR-16 molecules to form a nano-delivery system. The stability, particle size, potential and morphology of the nanoparticles were determined by agarose gel electrophoresis, particle size potentiometer and transmission electron microscopy. CCK-8 assay was used to assess the toxicity of the polypeptides in ovarian cancer cells. Stem loop qRT-PCR and living cell imaging were used to verify the uptake efficiency and intracellular distribution of the nanoparticles. Flow cytometry and Western blotting were performed to verify the effect of the nanoparticles for enhancing cisplatin sensitivity of ovarian cancer cells and explore the possible mechanism.

OBJECTIVE

R9-SS-R9/miR-16 and cRGD-R9-SS-R9/miR-16 nanoparticles were successfully prepared. The nanoparticles, with a particle size below 150 nm, a dispersity index less than 0.1 and a potential of about 40 mV, showed a good serum stability. The polypeptide material had no obvious cytotoxicity. The miR-16/polypeptide nanoparticles could be efficiently absorbed by human ovarian cancer cells and were distributed in the cytoplasm. The nanoparticles significantly increased the intracellular expression level of miR-16 (P < 0.001) and decreased the expression of Bcl-2 and Chk-1 proteins in ovarian cancer cells, thus enabling miR-16 to promote apoptosis and enhance cisplatin sensitivity of the cells.

OBJECTIVE

We successfully prepared a miR-16/polypeptide nano-delivery system for targeted delivery of miR-16 to ovarian cancer cells for enhancing cisplatin sensitivity of the cancer cells.

POS0522 PREVALENCE OF BRONCHIECTASIS IN RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Background:

Bronchiectasis is a known extra-articular manifestation of rheumatoid arthritis (RA) and can lead to decreased quality of life as well as increased risk for infection and mortality. Understanding the burden of bronchiectasis in RA may lead to a better understanding of pathogenesis and improved management. We performed a systematic review and meta-analysis to determine the prevalence of bronchiectasis in RA.

Objectives:

We investigated the prevalence of RA-related bronchiectasis (RA-BR) using a systematic review and meta-analysis.

Methods:

We followed the PRISMA-P 2015 guideline for systematic reviews and registered this analysis (ID#199080) on PROSPERO. We queried PubMed and EMBASE databases using the search strategy “rheumatoid arthritis; AND; bronchiectasis” as of July 31, 2020. The inclusion and exclusion criteria were assessed for study eligibility by two independent abstractors. Exclusion criteria included: (1) non-primary literature (i.e., review articles, editorials); (2) case reports involving less than 5 patients; (3) published in a language other than English; (4) did not relate to both RA and bronchiectasis; and (5) studies not involving humans (e.g., mouse models). After the initial screen, we conducted a full text review to verify that inclusion criteria were met: (1) reported frequency of RA-BR and denominator of all RA patients in the study sample. Data including type of study design, method of RA-BR detection, and RA characteristics were extracted by two independent abstractors. We performed meta-analyses using random effects models to estimate prevalence of RA-BR among RA overall and restricted to retrospective or prospective studies.

Results:

Out of a total of 208 studies, 37 studies were identified that reported frequency of RA-BR among RA. The included studies had heterogeneous methods to identify RA-BR that were based on either clinical or research chest computed tomography (CT) imaging and had varying methods to adjudicate images. Some studies focused on patients with respiratory symptoms or suspected RA-associated interstitial lung disease (RA-ILD). There were a total of 8,646 patients with RA, and 612 were identified as having RA-BR. The pooled overall prevalence of RA-BR in the random effects meta-analysis was 18.2% (95%CI 13.3-23.7%, Figure 1). Among prospective studies (n=24), the prevalence of RA-BR in the meta-analysis was 20.7% (95% CI 14.7-27.4%). Among retrospective studies (n=13) reporting RA-BR, the prevalence was 14.5% (95% CI 7.2-23.7%). Prevalence was lowest in retrospective studies where RA-BR was identified through clinical care (e.g., two large retrospective studies that investigated 4,000 and 1,129 RA patients reported RA-BR prevalence of 0.6% and 2.7%, respectively). The two largest prospective studies that incorporated a research protocol performing chest CT imaging on all enrolled patients investigated 150 and 332 patients with RA and reported a RA-BR prevalence of 8.0% and 9.6%, respectively. Smaller studies of both study design types generally reported higher prevalence of RA-BR.

Figure 1.

Pooled prevalence of RA-related bronchiectasis in RA among all studies identified (n=37).

Conclusion:

The prevalence of RA-BR in this systematic review and meta-analysis was 18.2%, emphasizing that bronchiectasis is a common extra-articular feature of RA. However, some studies may have identified subclinical RA-BR through research imaging or RA-BR may have been secondary to RA-ILD. Future studies should standardize methods to identify RA-BR cases and investigate the natural history and clinical course given the relatively high prevalence that we report.

Disclosure of Interests:

Lily Martin: None declared, Lauren Prisco: None declared, Weixing Huang: None declared, Gregory McDermott: None declared, Nancy Shadick Consultant of: Consultant < 5K Bristol-Myers Squibb, Grant/research support from: BMS Amgen Lilly, Mallinckrodt, and Sanofi, Tracy Doyle Consultant of: Boehringer Ingelheim (<5K), Grant/research support from: Bristol Myers Squibb and Genentech, Jeffrey Sparks Consultant of: Bristol-Myers Squibb, Gilead, Inova Diagnostics, Optum, and Pfizer, Grant/research support from: Bristol-Myers Squibb

Absent Cortical Venous Filling Is Associated with Aggravated Brain Edema in Acute Ischemic Stroke

BACKGROUND AND PURPOSE

Predicting malignant cerebral edema can help identify patients who may benefit from appropriate evidence-based interventions. We investigated whether absent cortical venous filling is associated with more pronounced early brain edema, which leads to malignant cerebral edema.

MATERIALS AND METHODS

Patients with acute ischemic stroke caused by large-vessel occlusion in the MCA territory who presented between July 2017 and September 2019 to our hospital were included. Collateral filling was rated using the modified Tan scale on CTA, and good collaterals were defined as a score of 2-3. The Cortical Vein Opacification Score (COVES) was calculated, and absent cortical venous filling was defined as a score of 0. Early brain edema was determined using net water uptake on baseline CT images. Malignant cerebral edema was defined as a midline shift of ≥5 mm on follow-up imaging or a massive cerebral swelling leading to decompressive hemicraniectomy or death. Multivariate linear and logistic regression models were performed to analyze data.

RESULTS

A total of 163 patients were included. Net water uptake was significantly higher in patients with absent than in those with favorable cortical venous filling (8.1% versus 4.2%; P < .001). In the multivariable regression analysis, absent cortical venous filling (β = 2.04; 95% CI, 0.75-3.32; P = .002) was significantly and independently associated with higher net water uptake. Absent cortical venous filling (OR, 14.68; 95% CI, 4.03-53.45; P < .001) and higher net water uptake (OR, 1.29; 95% CI, 1.05-1.58; P = .016) were significantly associated with increased likelihood of malignant cerebral edema.

CONCLUSIONS

Patients with absent cortical venous filling were associated with an increased early brain edema and a higher risk of malignant cerebral edema. These patients may be targeted for optimized adjuvant antiedematous treatment.

[Clinical efficacy and safety analysis of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma: a multicenter retrospective study]

Objective: To analyze the clinical efficacy and safety of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma (HCC). Methods: Ninety-four cases with mid-and advanced-stage HCC who received camrelizumab combined with apatinib as second-line treatment were enrolled. Routine blood test, blood biochemical indexes, tumor stage, tumor imaging characteristics, previous treatment strategies and other clinical data before treatment were documented. Imaging examination follow-up results and adverse reactions during treatment were followed up until the end of follow-up or loss of follow-up or death. Kaplan-Meier method was used to analyze the clinical efficacy. Results: As of the last follow-up, 94 cases with mid-and advanced-stage HCC had received camrelizumab combined with apatinib as second-line treatment. Among them, 15 cases were lost to follow-up, 31 cases died, and 48 cases survived. The overall remission rate was 31.9%. The overall disease control rate was 71.3%. The median time to disease-free progression was 6.6 months. The median time to disease progression was not yet available. The 1-year cumulative survival rate was 62.3%. Grade 3 and above adverse reactions mainly included were thrombocytopenia (7.4%), abdominal pain (4.3%), active hepatitis (4.3%), leukopenia (4.3%), diarrhea (3.2%), hand-foot syndrome (3.2%). All adverse reactions were effectively controlled. Conclusion: Camrelizumab combined with apatinib can effectively prolong the survival period of patients with mid-and advanced-stage HCC, and it is well tolerated.